Retrieve available abstracts of 16 articles: HTML format
Single Articles
March 2025
YOKOTA H, Sato K, Sakamoto S, Okuda Y, et al Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of
osimertinib in patients with non-small cell lung cancer.
Cancer Chemother Pharmacol. 2025;95:49. PubMedAbstract available
January 2025
FUNAISHI K, Yamaguchi K, Tanahashi H, Kurose K, et al HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of
anti-PD-1/PD-L1 antibody in NSCLC.
Cancer Chemother Pharmacol. 2025;95:28. PubMedAbstract available
CHENG CY, Chuang WC, Lin CP, Li CH, et al Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell
lung cancer: a cellular study.
Cancer Chemother Pharmacol. 2025;95:20. PubMedAbstract available
December 2024
GEZELIUS E, Planck M, Hazem B, Nagpal S, et al Intrathecal pemetrexed for leptomeningeal metastases in a patient with
ALK-rearranged lung adenocarcinoma: a case report.
Cancer Chemother Pharmacol. 2024;95:6. PubMedAbstract available
DE ROUW N, Beunders R, Hartmann O, Schulte J, et al A comparison of the renal function biomarkers serum creatinine, pro-enkephalin
and cystatin C to predict clearance of pemetrexed.
Cancer Chemother Pharmacol. 2024;94:799-806. PubMedAbstract available
September 2024
LIN L, van der Noort V, Steeghs N, Ruiter G, et al A joint model of longitudinal pharmacokinetic and time-to-event data to study
exposure-response relationships: a proof-of-concept study with alectinib.
Cancer Chemother Pharmacol. 2024;94:453-459. PubMedAbstract available
July 2024
YAMAMOTO N, Koyama T, Sato J, Yoshida T, et al Phase I study of the anti-TIGIT antibody tiragolumab in combination with
atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Cancer Chemother Pharmacol. 2024;94:109-115. PubMedAbstract available
April 2024
XU X, Liu Y, Gong Q, Ma L, et al PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell
lung cancer.
Cancer Chemother Pharmacol. 2024 Apr 12. doi: 10.1007/s00280-024-04668. PubMedAbstract available
URYU K, Imamura Y, Shimoyama R, Mase T, et al Prognostic impact of concomitant pH-regulating drugs in patients with non-small
cell lung cancer receiving epidermal growth factor receptor tyrosine kinase
inhibitors: the Tokushukai REAl-world Data project 01-S1.
Cancer Chemother Pharmacol. 2024 Apr 8. doi: 10.1007/s00280-024-04666. PubMedAbstract available
March 2024
HUO H, Feng Y, Tang Q Correction to: Inhibition of proteinase-activated receptor 2 (PAR2) decreased the
malignant progression of lung cancer cells and increased the sensitivity to
chemotherapy.
Cancer Chemother Pharmacol. 2024 Mar 26. doi: 10.1007/s00280-024-04646. PubMed
February 2024
MA X, Sun Z, Chen H, Cao L, et al 18beta-glycyrrhetinic acid suppresses Lewis lung cancer growth through protecting
immune cells from ferroptosis.
Cancer Chemother Pharmacol. 2024 Feb 21. doi: 10.1007/s00280-024-04639. PubMedAbstract available
January 2024
YU F, Huo H, Tang Q Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant
progression of lung cancer cells and increased the sensitivity to chemotherapy.
Cancer Chemother Pharmacol. 2024 Jan 4. doi: 10.1007/s00280-023-04630. PubMedAbstract available
LI MY, Zhang J, Lu X, Zhou D, et al Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis
in lung adenocarcinoma cells.
Cancer Chemother Pharmacol. 2024;93:41-54. PubMedAbstract available
November 2023
WANG X, Gu S, Wen J, Zhang L, et al Association between chemotherapy-induced myelosuppression and curative efficacy
of 2-cycle chemotherapy in small cell lung cancer.
Cancer Chemother Pharmacol. 2023 Nov 5. doi: 10.1007/s00280-023-04608. PubMedAbstract available
MA Y, Chen Q, Zhang Y, Xue J, et al Pharmacokinetics, safety, tolerability, and feasibility of apatinib in
combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a
drug-drug interaction study.
Cancer Chemother Pharmacol. 2023;92:411-418. PubMedAbstract available
September 2023
CHENG M, Yang F, Yang Y, Gao X, et al Correlation analysis between camrelizumab trough concentration levels and
efficacy or safety in East Asian patients with advanced lung cancer.
Cancer Chemother Pharmacol. 2023 Sep 23. doi: 10.1007/s00280-023-04590. PubMedAbstract available